| 000 | 01528 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516090049.0 | ||
| 264 | 0 | _c20120809 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1873-2968 | ||
| 024 | 7 |
_a10.1016/j.bcp.2012.04.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGhassabian, Sussan | |
| 245 | 0 | 0 |
_aRole of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. _h[electronic resource] |
| 260 |
_bBiochemical pharmacology _cJul 2012 |
||
| 300 |
_a215-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBenzenesulfonates _xmetabolism |
| 650 | 0 | 4 | _aCatalytic Domain |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInactivation, Metabolic |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 | _aProtein Conformation |
| 650 | 0 | 4 |
_aPyridines _xmetabolism |
| 650 | 0 | 4 | _aSorafenib |
| 700 | 1 | _aRawling, Tristan | |
| 700 | 1 | _aZhou, Fanfan | |
| 700 | 1 | _aDoddareddy, Munikumar R | |
| 700 | 1 | _aTattam, Bruce N | |
| 700 | 1 | _aHibbs, David E | |
| 700 | 1 | _aEdwards, Robert J | |
| 700 | 1 | _aCui, Pei H | |
| 700 | 1 | _aMurray, Michael | |
| 773 | 0 |
_tBiochemical pharmacology _gvol. 84 _gno. 2 _gp. 215-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bcp.2012.04.001 _zAvailable from publisher's website |
| 999 |
_c21712643 _d21712643 |
||